Effect Of Psychoeducation On Substance Craving Levels And Psychological Resilience

May 6, 2026 updated by: Fatima Ozdemir Sigva, University of Gaziantep

Effect Of Psychoeducation On Substance Craving Levels And Psychological Resilience İn Patients With Substance Use Disorder Under Probation Supervision

What is known on the subject? Substance use disorder is a chronic condition with high relapse risk, and individuals under probation supervision are particularly vulnerable. Psychoeducation and psychological resilience are important factors in reducing craving and improving treatment outcomes.

What the paper adds to existing knowledge

What are the implications for practice? Psychoeducation can be effectively used by psychiatric nurses in probation settings to support recovery. Strengthening psychological resilience should be considered a key target in addiction interventions.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Introduction: Substance use disorder is a major public health problem that adversely affects individuals' physical, psychological, and social functioning. For individuals under probation supervision, preventing relapse and controlling substance use are of critical importance. Psychoeducation is an important psychosocial intervention with the potential to reduce craving and enhance psychological resilience.

Aim: This study aimed to examine the effect of psychoeducation on substance craving levels and psychological resilience in individuals diagnosed with substance use disorder under probation supervision.

Methods: A quasi-experimental pretest-posttest control group design was used. The study included 60 participants (30 intervention, 30 control). A structured psychoeducation program was applied to the intervention group, while the control group continued to receive standard care. Data were collected using a personal information form, the substance craving scale, and the Adult Resilience Scale.

Discussion: Psychoeducation is thought to reduce substance craving and increase psychological resilience by strengthening cognitive and emotional regulation in the addiction process.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Mardin, Turkey (Türkiye), 47200
        • Mardin Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Being 18 years of age or older
  2. Being under probation supervision
  3. Having a diagnosis of substance use disorder according to DSM-5
  4. Being able to attend psychoeducation sessions regularly
  5. Providing written informed consent
  6. Not having participated in a similar psychoeducation program within the past 6 months

Exclusion Criteria:

  1. Diagnosis of schizophrenia, severe psychotic disorder, or cognitive impairment
  2. Being in an acute withdrawal period
  3. Inability to attend sessions regularly
  4. Presence of severe communication or behavioral disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental
A structured psychoeducation program was administered to individuals with substance use disorder under probation supervision. The program included six weekly sessions focusing on relapse prevention, coping strategies, psychological resilience, and substance craving management. The intervention was delivered by a trained mental health professional over a six-week period, with one 60-minute session per week.
Behavioral: Structured Psychoeducation Program
A structured psychoeducation program was implemented for individuals with substance use disorder under probation supervision. The program focused on relapse prevention, coping strategies, psychological resilience, and craving management. It was delivered in weekly group sessions over six weeks by a trained mental health professional in a hospital setting. Each session lasted 60 minutes. The intervention was designed to support rehabilitation and treatment processes in outpatient probation services.
Other Names:
  • Psychoeducation; Cognitive Behavioral Psychoeducation; Relapse Prevention Psychoeducation
No Intervention: Control
During the study period, no intervention or psychoeducation program was applied to the participants in the control group. Individuals in this group were monitored solely within the scope of routine probation procedures and were subjected only to pre-test and post-test measurements. Throughout the intervention period, the data of the control group were evaluated within the natural course, without any additional educational or psychosocial intervention. Upon completion of the study, in accordance with ethical principles, it was stated that the same psychoeducation program would be offered to participants who requested it.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Substance Craving Level
Time Frame: Baseline (pre-intervention) and immediately after the 6-week intervention
Psychological resilience was measured using a validated resilience scale . Higher scores indicate greater resilience.
Baseline (pre-intervention) and immediately after the 6-week intervention
Psychological Resilience
Time Frame: Baseline (pre-intervention) and immediately after the 6-week intervention
Psychological resilience was measured using a validated resilience scale .Higher scores indicate greater resilience.
Baseline (pre-intervention) and immediately after the 6-week intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Treatment Engagement
Time Frame: During the 6-week intervention period
Attendance and participation rates in psychoeducation sessions were recorded to evaluate program adherence.
During the 6-week intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Gaziantep

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 20, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 20, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 20, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 29, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MAU-SBF-PSYEDU-2025-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychoeducation Study

Clinical Trials on Structured Psychoeducation Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings